Neoadjuvant Immunotherapy Demonstrates Promising Results in Colon Cancer

Dr. Myriam Chalabi, an oncologist at Netherlands Cancer Institute, spoke with the Oncology Brothers (Drs. Rohit and Rahul Gosain) to discuss the NICHE-2 study, which assessed the use of neoadjuvant immunotherapy in deficient mismatch repair (dMMR) colon cancer. In this study consisting of 112 patients, adjuvant immunotherapy yielded highly robust pathologic responses in 100% of dMMR tumors, indicating the strong potential for adjuvant immunotherapy to become standard of care.